MARKETS PERPS LIVE123 SOCIAL

Cash

Portfolio

Search

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions Finance Tech & Science

Portfolio

Search

Product

Perpetual Futures Markets Incentive program Institutions API & developers

Company

About Kalshi Research Blog Careers Policy Center Brand Kit

Help

Help Center FAQ Fee schedule Trading hours Regulatory

© 2026 Kalshi Inc. · All rights reserved

Privacy Data Terms of Service Trading Prohibitions FAQ for Finance Professionals

Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions Finance Tech & Science

FDA decision: Gedatolisib by Celcuity Inc. (July 2026) Odds & Predictions

Financials

FDA decision: Gedatolisib by Celcuity Inc. (July 2026)

Series Image

Financials

FDA decision: Gedatolisib by Celcuity Inc. (July 2026)

Full Approval

Yes

Full Approval

Yes

Conditional / Accelerated Approval

No

Conditional / Accelerated Approval

No

No Decision

No

No Decision

No

2 more

Full Approval

Dollars$

Odds

0% chance

Max payout

$0

$12,553 vol

1D

1W

1M

ALL